Skye Bioscience R&D Spending Growth & History (SKYE)
Skye Bioscience's r&d spending was $42.4M for fiscal 2025.
View full Skye Bioscience company overviewSkye Bioscience annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.4M | $23.7M | +126.51% |
| 2024 | 2024-12-31 | $18.7M | $12.9M | +221.36% |
| 2023 | 2023-12-31 | $5.8M | −$192,344 | −3.20% |
| 2022 | 2022-12-31 | $6.0M | $3.1M | +105.08% |
| 2021 | 2021-12-31 | $2.9M | $987,026 | +50.76% |
| 2020 | 2020-12-31 | $1.9M | −$293,545 | −13.12% |
| 2019 | 2019-12-31 | $2.2M | $1.9M | +578.24% |
| 2018 | 2018-12-31 | $329,966 | $18,664 | +6.00% |
| 2017 | 2017-12-31 | $311,302 | −$627,738 | −66.85% |
| 2016 | 2016-12-31 | $939,040 | $362,947 | +63.00% |
| 2015 | 2015-12-31 | $576,093 | $348,593 | +153.23% |
| 2014 | 2014-12-31 | $227,500 | — | — |
Skye Bioscience quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.9M | −$10.4M | −72.51% |
| Q1 2026 | 2026-03-31 | $7.9M | $738,423 | +10.26% |
| Q4 2025 | 2025-12-31 | $11.5M | $3.7M | +47.17% |
| Q3 2025 | 2025-09-30 | $9.4M | $4.5M | +91.62% |
| Q2 2025 | 2025-06-30 | $14.3M | $10.3M | +251.52% |
| Q1 2025 | 2025-03-31 | $7.2M | $5.3M | +269.76% |
| Q4 2024 | 2024-12-31 | $7.8M | $6.2M | +389.68% |
| Q3 2024 | 2024-09-30 | $4.9M | $3.6M | +289.22% |
| Q2 2024 | 2024-06-30 | $4.1M | $2.3M | +128.06% |
| Q1 2024 | 2024-03-31 | $1.9M | $761,570 | +64.27% |
| Q4 2023 | 2023-12-31 | $1.6M | $54,220 | +3.53% |
| Q3 2023 | 2023-09-30 | $1.3M | −$527,071 | −29.58% |
| Q2 2023 | 2023-06-30 | $1.8M | $361,280 | +25.31% |
| Q1 2023 | 2023-03-31 | $1.2M | −$80,773 | −6.38% |
| Q4 2022 | 2022-12-31 | $1.5M | $423,896 | +38.07% |
| Q3 2022 | 2022-09-30 | $1.8M | $1.5M | +443.65% |
| Q2 2022 | 2022-06-30 | $1.4M | $546,482 | +62.05% |
| Q1 2022 | 2022-03-31 | $1.3M | $655,997 | +107.60% |
| Q4 2021 | 2021-12-31 | $1.1M | $743,325 | +200.87% |
| Q3 2021 | 2021-09-30 | $327,731 | −$18,486 | −5.34% |
| Q2 2021 | 2021-06-30 | $880,672 | $452,143 | +105.51% |
| Q1 2021 | 2021-03-31 | $609,656 | −$189,956 | −23.76% |
| Q4 2020 | 2020-12-31 | $370,053 | −$345,872 | −48.31% |
| Q2 2020 | 2020-09-30 | $346,217 | −$166,787 | −32.51% |
| Q1 2020 | 2020-06-30 | $428,529 | −$259,512 | −37.72% |
| Q4 2019 | 2020-03-31 | $799,612 | $478,626 | +149.11% |
| Q4 2019 | 2019-12-31 | $715,925 | $478,250 | +201.22% |
| Q3 2019 | 2019-09-30 | $513,004 | $445,713 | +662.37% |
| Q2 2019 | 2019-06-30 | $688,041 | $688,041 | — |
| Q1 2019 | 2019-03-31 | $320,986 | $295,986 | +1183.94% |
| Q4 2018 | 2018-12-31 | $237,675 | $167,674 | +239.53% |
| Q3 2018 | 2018-09-30 | $67,291 | −$21,259 | −24.01% |
| Q2 2018 | 2018-06-30 | $0 | −$60,651 | — |
| Q1 2018 | 2018-03-31 | $25,000 | −$67,100 | −72.86% |
| Q4 2017 | 2017-12-31 | $70,001 | −$193,199 | −73.40% |
| Q3 2017 | 2017-09-30 | $88,550 | $8,025 | +9.97% |
| Q2 2017 | 2017-06-30 | $60,651 | −$399,306 | −86.81% |
| Q1 2017 | 2017-03-31 | $92,100 | −$43,258 | −31.96% |
| Q4 2016 | 2016-12-31 | $263,200 | −$80,031 | −23.32% |
| Q3 2016 | 2016-09-30 | $80,525 | −$71,763 | −47.12% |
| Q2 2016 | 2016-06-30 | $459,957 | $416,583 | +960.44% |
| Q1 2016 | 2016-03-31 | $135,358 | $98,158 | +263.87% |
| Q4 2015 | 2015-12-31 | $343,231 | — | — |
| Q3 2015 | 2015-09-30 | $152,288 | −$42,712 | −21.90% |
| Q2 2015 | 2015-06-30 | $43,374 | — | — |
| Q1 2015 | 2015-03-31 | $37,200 | — | — |
| Q3 2014 · Sep 30 | 2014-09-30 | $195,000 | — | — |
Skye Bioscience r&d spending trends
Over the last five fiscal years, Skye Bioscience's r&d spending increased from $1.9M to $42.4M, a change of $40.4M. The latest reported quarter, Q2 2026, shows $3.9M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Skye Bioscience source filings ↗